Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2026—For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—Alz-heimer’s disease has been linked to remarkably bright news as of late. Blood-based biomarkers, including two that garnered FDA approval last year, have cracked open the door to earlier diagnoses and therapeutic interventions, as well as the potential to reach more patients.
March 2026—An international panel of experts in multiple sclerosis and cerebrospinal fluid diagnostics reached a consensus in 2023, and they recommended including the determination of intrathecal kappa free light chain synthesis in the next revision of MS diagnostic criteria as an additional tool to measure intrathecal immunoglobulin synthesis.
March 2026—More flexibility and less burden sum up the personnel requirement changes in the accreditation program checklists released in December last year. The revisions to the CAP checklists stem from changes that the Centers for Medicare and Medicaid Services announced on June 23, 2025 in response to feedback the CMS had received about what it required in the CLIA final rule implemented on Dec. 28, 2024. The announcements were in CMS memorandum QSO-25-21-CLIA (CLIA Enforcement Discretion and Clarification on Personnel Regulations) and QSO-25-10-CLIA Revised (Revisions to State Operations Manual, Appendix C–Advance Copy).
March 2026—Newer sepsis diagnostics, including monocyte distribution width, Intellisep, and MeMed BV, show promise in clinical studies but have limitations.
March 2026—Laboratory leaders from various health systems discussed strategies to navigate competition and ensure growth.
March 2026—A University of Washington study analyzed HCV testing costs across its system from 2017 to 2024, focusing on the public county hospital ED where one-third of diagnoses occur.
March 2026—Rapid advances in genomic sequencing are reshaping microbial classification and nomenclature, creating challenges for clinical microbiology laboratories.
March 2026—A roundtable discussion focused on improving workflow efficiency in urinalysis, highlighting the potential of AI to enhance reflex testing by integrating test results with EHR data.
March 2026—International medical graduates are crucial to the American healthcare system, particularly in pathology, where they make up a significant portion of the workforce.
March 2026—Continuous glucose monitoring is recommended for type 1 and type 2 diabetes patients, particularly those using insulin.
